About Pantherna Therapeutics

Pantherna Therapeutics is a privately-held biopharmaceutical company developing first-in-class therapeutics for vascular diseases. Pantherna’s innovative technology platform is based on advanced nanoparticles for the delivery and expression of therapeutic mRNA drugs in the endothelium. Pantherna is based in Hennigsdorf (Brandenburg) close to Berlin, Germany.

Press releases

Pantherna Logo
11. January 2022

Pantherna Therapeutics secures EUR 4.0 Mio. follow-on financing to advance its therapeutic mRNA development programs   

Hennigsdorf, January 11, 2022 – Pantherna Therapeutics today announces the successful completion of a follow-on financing round totaling EUR 4.0 Mio. led by existing investors Riesner Verwaltungs GmbH and High-Tech Gründerfonds. The proceeds of this round will be used to accelerate preclinical development activities for its lead program PAN004, an mRNA-based therapeutic for Acute Respiratory Distress Syndrome (ARDS).   ARDS causes a life-threatening damage to the lungs induced
3. July 2019

“First-in-Class“ mRNA-therapeutics for vascular diseases: Pantherna Therapeutics receives 7-digit investment

The life science start-up Pantherna Therapeutics secures €3.5 million in a successful seed-financing round. The start-up presents a proprietary, innovative technology platform for the development of novel mRNA therapeutics to treat Acute Respiratory Distress Syndrome (ARDS), a severe lung disease. The funds will be used to advance R&D activities and hire additional scientific staff. Investors are the High-Tech Gründerfonds (HTGF), European Business Angel Prof. Detlev Riesner


Neuendorfstrasse 20b
16761 Hennigsdorf

In portfolio

27. May 2019

Dr. Anke Caßing

Principal / Authorized Signatory